Last reviewed · How we verify
Mannitol (Aridol) — Competitive Intelligence Brief
marketed
Osmotic agent / Diagnostic bronchial challenge agent
Respiratory / Diagnostics
Small molecule
Live · refreshed every 30 min
Target snapshot
Mannitol (Aridol) (Mannitol (Aridol)) — University of Saskatchewan. Mannitol is an osmotic agent that draws fluid into the airways to increase airway hydration and mucus clearance, used diagnostically to assess airway hyperresponsiveness.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Mannitol (Aridol) TARGET | Mannitol (Aridol) | University of Saskatchewan | marketed | Osmotic agent / Diagnostic bronchial challenge agent |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Osmotic agent / Diagnostic bronchial challenge agent class)
- University of Saskatchewan · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Mannitol (Aridol) CI watch — RSS
- Mannitol (Aridol) CI watch — Atom
- Mannitol (Aridol) CI watch — JSON
- Mannitol (Aridol) alone — RSS
- Whole Osmotic agent / Diagnostic bronchial challenge agent class — RSS
Cite this brief
Drug Landscape (2026). Mannitol (Aridol) — Competitive Intelligence Brief. https://druglandscape.com/ci/mannitol-aridol. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab